KLISBio to disclose state-of-the-art tissue-engineered technology platform at 2022 CG Musculoskeletal Conference

KLISBio, a regenerative medicine company utilizing silk-based technology, confirmed its participation in the 2022 CG Musculoskeletal Conference held alongside the American Academy of Orthopaedic Surgeons Annual Meeting in Chicago from March 22-26, 2022. Jason Schense, serving as Chief Business Officer and Chief Operating Officer, represented the organization at the event.

The company sought to expand professional relationships with potential investors and industry partners while showcasing SILKBridge, its first product candidate designed for peripheral nerve repair. This absorbable medical device, composed of Bombyx mori silk fibroin, addresses surgical repair of peripheral nerve discontinuities and was anticipated for U.S. market availability in 2023.

KLISBio's silk-based technology platform combines traditional silk processing expertise with contemporary biomedical innovation, utilizing purified materials without chemical cross-linking. The platform targets multiple clinical areas including peripheral nerve injuries, vascular diseases, bone defects, and tendon damage.

The organization assembled an experienced leadership team featuring Grecchi as CEO, Antonio Alessandrino as President and Chief Technology Officer, Giuliano Freddi as Chief Scientific Officer, and Jason Schense in dual roles. Rodrigo Bianchi joined as Board Chairman, bringing over thirty years of healthcare industry experience.

KLISBio maintains headquarters in Bresso, Milan, Italy, and operates several developmental programs for vascular grafts, bone substitutes, and rotator cuff repair solutions.